We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.17B
AUM Growth
+$187M
Cap. Flow
-$13.4M
Cap. Flow %
-0.62%
Top 10 Hldgs %
27.68%
Holding
163
New
13
Increased
39
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$28M
2
IRTC icon
iRhythm Holdings
IRTC
+$17.5M
3
PBYI icon
Puma Biotechnology
PBYI
+$13.4M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.8M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.9M
2
HUM icon
Humana
HUM
+$31.9M
3
HOLX
Hologic
HOLX
+$19.1M
4
MDT icon
Medtronic
MDT
+$12.7M
5
WBA
Walgreens Boots Alliance
WBA
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 80.49%
2 Financials 3.75%
3 Consumer Discretionary 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
51
DELISTED
Audentes Therapeutics, Inc
BOLD
$14.7M 0.68%
525,000
-70,200
-12% -$1.52M
BAX icon
52
Baxter International
BAX
$14.2B
$14.4M 0.67%
230,000
– –
AMRN
53
Amarin Corp
AMRN
$303M
$14M 0.65%
200,000
-12,500
-6% -$885K
FOLD
54
DELISTED
Amicus Therapeutics
FOLD
$13.7M 0.63%
910,000
+152,500
+20% +$2.02M
ASMB icon
55
Assembly Biosciences
ASMB
$529M
$13.6M 0.63%
32,500
– –
MDGL icon
56
Madrigal Pharmaceuticals
MDGL
$11.8B
$12.4M 0.57%
275,000
-265,000
-49% -$4.96M
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$29.3B
$12.3M 0.57%
105,000
– –
EHC icon
58
Encompass Health
EHC
$12.4B
$12.3M 0.57%
333,105
– –
NVTA
59
DELISTED
Invitae Corporation
NVTA
$12.2M 0.56%
1,306,000
+106,000
+9% +$1.01M
KITE
60
DELISTED
Kite Pharma, Inc.
KITE
$12.2M 0.56%
68,000
+500
+0.7% +$69.7K
SRPT icon
61
Sarepta Therapeutics
SRPT
$1.77B
$11.8M 0.54%
259,200
+54,200
+26% +$2.17M
BMRN icon
62
BioMarin Pharmaceuticals
BMRN
$12.3B
$11.6M 0.54%
125,000
– –
ALGN icon
63
Align Technology
ALGN
$12.3B
$11.4M 0.53%
61,300
+38,300
+167% +$6.56M
ACRS icon
64
Aclaris Therapeutics
ACRS
$825M
$11.4M 0.52%
440,000
– –
PRTK
65
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.3M 0.52%
450,000
-150,000
-25% -$3.49M
ARDX icon
66
Ardelyx
ARDX
$988M
$11.2M 0.52%
2,000,000
– –
DERM
67
DELISTED
Dermira, Inc.
DERM
$10.8M 0.5%
400,000
+12,400
+3% +$324K
XENT
68
DELISTED
Intersect ENT, Inc
XENT
$10.7M 0.5%
345,000
– –
ALDR
69
DELISTED
Alder Biopharmaceuticals
ALDR
$10.7M 0.49%
875,000
+693,000
+381% +$7.23M
ASND icon
70
Ascendis Pharma A/S
ASND
$16.8B
$10.2M 0.47%
280,000
-45,000
-14% -$1.29M
JUNO
71
DELISTED
Juno Therapeutics, Inc.
JUNO
$10.1M 0.47%
225,000
– –
TVTX icon
72
Travere Therapeutics
TVTX
$5.78B
$9.96M 0.46%
400,000
– –
CO
73
DELISTED
Global Cord Blood Corporation
CO
$9.79M 0.45%
880,000
– –
ACHN
74
DELISTED
Achillion Pharmaceuticals
ACHN
$9.57M 0.44%
2,131,400
+406,400
+24% +$1.8M
NDRM
75
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$9.25M 0.43%
237,700
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rock Springs Capital Management held 163 positions worth $2.17B, up 9.5% from $1.98B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q3 2017 filing shows 13 new, 39 increased, 20 reduced and 16 closed positions. Its largest new stake was iRhythm Holdings: 386,000 shares worth $20M. The largest sale was Allergan plc, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2017 buy was iRhythm Holdings: 386,000 shares worth $20M.
  • Rock Springs Capital Management added most to UnitedHealth in Q3 2017, an estimated $28M increase.
  • Rock Springs Capital Management's biggest Q3 2017 reduction was Medtronic, cutting an estimated $12.7M.
  • Rock Springs Capital Management fully exited Allergan plc in Q3 2017, selling an estimated $37.9M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $2.17B portfolio in Q3 2017.
  • Rock Springs Capital Management opened 13 new positions and closed 16 in Q3 2017.
  • Rock Springs Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.17B.

Based on Rock Springs Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.